Alector (ALEC)

• Market cap: $115M
• 1 day: -5.69%
• 5 days: -10.08%
• 1 month: -17.73%
• 3 months: -38.62%
• 6 months: -74.51%
• Year to date: -38.62%
• 1 year: -81.17%
• 5 years: -94.70%
• 10 years: -93.56%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Employees: 238

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

154% more call options, than puts

Call options by funds: $399K | Put options by funds: $157K

21% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 38

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

2.45% less ownership

Funds ownership: 77.35% [Q3] → 74.9% (-2.45%) [Q4]

6% less funds holding

Funds holding: 159 [Q3] → 149 (-10) [Q4]

21% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 39

61% less capital invested

Capital invested by funds: $351M [Q3] → $139M (-$213M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 29% upside
• Avg. target: $4.25 266% upside
• High target: $7 503% upside

2 analyst ratings

• positive: 1 50%
• neutral: 0 0%
• negative: 1 50%

Morgan Stanley Sean Laaman 100% 1-year accuracy 1 / 1 met price target	29% upside $1.50	Underweight Assumed	7 Mar 2025
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 358 met price target	503% upside $7	Buy Reiterated	27 Feb 2025